RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Cecile M. Ronckers; Lieve Tytgat; Marry M. van den Heuvel-Eibrink; Jop Teepen; Leontine C M Kremer; Sarah Clement; Hanneke M. van Santen

doi:10.1016/j.ejca.2017.02.019

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Cecile M. Ronckers^*
, Lieve Tytgat
, Marry M. van den Heuvel-Eibrink
, Jop Teepen
, Leontine C M Kremer
, Sarah Clement
, Hanneke M. van Santen

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	21-23
Number of pages	3
Journal	European Journal of Cancer
Volume	77
DOIs	https://doi.org/10.1016/j.ejca.2017.02.019
Publication status	Published - May 2017

Access to Document

10.1016/j.ejca.2017.02.019

riskFinal published version, 369 KBLicence: Taverne

Cite this

Ronckers, C. M., Tytgat, L., van den Heuvel-Eibrink, M. M., Teepen, J., Kremer, L. C. M., Clement, S., & van Santen, H. M. (2017). RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152. European Journal of Cancer, 77, 21-23. https://doi.org/10.1016/j.ejca.2017.02.019

@article{70e47fa7e9af4320bb76aaaff9335f04,

title = "RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152",

author = "Ronckers, \{Cecile M.\} and Lieve Tytgat and \{van den Heuvel-Eibrink\}, \{Marry M.\} and Jop Teepen and Kremer, \{Leontine C M\} and Sarah Clement and \{van Santen\}, \{Hanneke M.\}",

note = "Funding Information: Dr. CM Ronckers is supported by Dutch Cancer Society grant \# UVA 2012-5517.",

year = "2017",

month = may,

doi = "10.1016/j.ejca.2017.02.019",

language = "English",

volume = "77",

pages = "21--23",

}

Ronckers, CM, Tytgat, L, van den Heuvel-Eibrink, MM, Teepen, J, Kremer, LCM, Clement, S & van Santen, HM 2017, 'RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152', European Journal of Cancer, vol. 77, pp. 21-23. https://doi.org/10.1016/j.ejca.2017.02.019

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152. / Ronckers, Cecile M.; Tytgat, Lieve; van den Heuvel-Eibrink, Marry M. et al.
In: European Journal of Cancer, Vol. 77, 05.2017, p. 21-23.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - RE

T2 - Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

AU - Ronckers, Cecile M.

AU - Tytgat, Lieve

AU - van den Heuvel-Eibrink, Marry M.

AU - Teepen, Jop

AU - Kremer, Leontine C M

AU - Clement, Sarah

AU - van Santen, Hanneke M.

N1 - Funding Information: Dr. CM Ronckers is supported by Dutch Cancer Society grant # UVA 2012-5517.

PY - 2017/5

Y1 - 2017/5

UR - https://www.scopus.com/pages/publications/85016139001

U2 - 10.1016/j.ejca.2017.02.019

DO - 10.1016/j.ejca.2017.02.019

M3 - Comment/Letter to the editor

C2 - 28359832

AN - SCOPUS:85016139001

SN - 0959-8049

VL - 77

SP - 21

EP - 23

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Ronckers CM, Tytgat L, van den Heuvel-Eibrink MM, Teepen J, Kremer LCM, Clement S et al. RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152. European Journal of Cancer. 2017 May;77:21-23. doi: 10.1016/j.ejca.2017.02.019

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Access to Document

Other files and links

Cite this

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152